Literature DB >> 18756586

A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI).

G Nijpels1, W Boorsma, J M Dekker, P J Kostense, L M Bouter, R J Heine.   

Abstract

BACKGROUND: We hypothesized that acarbose would delay conversion from impaired glucose tolerance (IGT) to type 2 diabetes by alleviating postprandial hyperglycaemia. Our study's main objective was to investigate the effect of acarbose in IGT-persons on their 2-h plasma glucose level and beta-cell function. SUBJECTS AND METHODS: The study included a random sample of 45-70-year-old residents of Hoorn, Netherlands, with mean fasting plasma glucose < 7.8 mmol/L and mean 2-h plasma glucose of 8.6-11.1 mmol/L (measured by two successive oral glucose tolerance tests). After a qualification period, participants were randomized to acarbose treatment or placebo. Insulin secretion and insulin sensitivity were measured by hyperglycaemic clamp. After a 3-year treatment, analyses were performed of both the intention-to-treat and the per-protocol groups.
RESULTS: Of the 12 093 residents who received postal invitations, 118 participants were randomized. The mean difference of the post-load plasma glucose after 3 years, was - 1.16 mmol/L (95% CI: - 2.03; - 0.17). The absolute risk reduction for diabetes was 6% (95% CI: - 9; 21). No effect was seen on insulin secretion and insulin sensitivity.
CONCLUSIONS: In patients with IGT, treatment with acarbose was associated with beneficial effects on 2-h plasma glucose levels but not with improvement of beta-cell function. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756586     DOI: 10.1002/dmrr.839

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

Review 1.  Sex-specific differences in diabetes prevention: a systematic review and meta-analysis.

Authors:  Anna Glechner; Jürgen Harreiter; Gerald Gartlehner; Sonja Rohleder; Alexander Kautzky; Jaakko Tuomilehto; Megan Van Noord; Angela Kaminski-Hartenthaler; Alexandra Kautzky-Willer
Journal:  Diabetologia       Date:  2014-12-03       Impact factor: 10.122

2.  Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).

Authors:  Tamara S Hannon; M S Kirkman; Yash R Patel; Robert V Considine; Kieren J Mather
Journal:  Diabetes Metab Res Rev       Date:  2014-11       Impact factor: 4.876

Review 3.  Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  J Sonya Haw; Karla I Galaviz; Audrey N Straus; Alysse J Kowalski; Matthew J Magee; Mary Beth Weber; Jingkai Wei; K M Venkat Narayan; Mohammed K Ali
Journal:  JAMA Intern Med       Date:  2017-12-01       Impact factor: 21.873

Review 4.  Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.

Authors:  Ruth L Coleman; Charles A B Scott; Zhihui Lang; M Angelyn Bethel; Jaakko Tuomilehto; Rury R Holman
Journal:  Cardiovasc Diabetol       Date:  2019-10-17       Impact factor: 9.951

5.  Characterization of Maltase and Sucrase Inhibitory Constituents from Rhodiola crenulata.

Authors:  Wen-Tai Li; Yu-Hsuan Chuang; Jung-Feng Hsieh
Journal:  Foods       Date:  2019-11-02

6.  Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Authors:  Suzanne Vl Moelands; Peter Lbj Lucassen; Reinier P Akkermans; Wim Jc De Grauw; Floris A Van de Laar
Journal:  Cochrane Database Syst Rev       Date:  2018-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.